XOMA
XOMA Royalty Corp. NASDAQ Listed Jun 6, 1986$41.29
Mkt Cap $500.8M
52w Low $22.29
92.6% of range
52w High $42.81
50d MA $33.19
200d MA $31.37
P/E (TTM)
27.1x
EV/EBITDA
36.7x
P/B
7.2x
Debt/Equity
1.3x
ROE
37.8%
P/FCF
166.5x
RSI (14)
—
ATR (14)
—
Beta
0.68
50d MA
$33.19
200d MA
$31.37
Avg Volume
216.9K
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
2200 Powell Street · EmeryVille, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.13 | 0.12 | +192.3% | 27.35 | +1.3% | +5.2% | +5.0% | +8.8% | +6.8% | +10.4% | — |
| Nov 12, 2025 | AMC | -0.02 | -0.35 | -1650.0% | 33.62 | +2.0% | -4.1% | -2.9% | -4.7% | -2.5% | -1.4% | — |
| Aug 13, 2025 | AMC | -0.12 | 0.48 | +500.0% | 30.89 | +1.0% | +2.3% | +1.6% | +2.8% | +3.8% | +5.1% | — |
| May 13, 2025 | AMC | -0.26 | 0.06 | +123.1% | 27.49 | -1.2% | -2.7% | -2.1% | -1.8% | -0.0% | -3.2% | — |
| Mar 17, 2025 | AMC | -0.29 | -0.46 | -58.6% | 20.73 | +1.3% | +0.8% | +0.8% | +1.6% | +0.7% | +1.0% | — |
| Nov 7, 2024 | AMC | -0.44 | -0.39 | +11.4% | 30.20 | +1.6% | +2.5% | +3.2% | +3.5% | -1.6% | -1.1% | — |
| Aug 13, 2024 | AMC | -0.26 | -0.28 | -7.7% | 26.46 | +0.9% | -1.1% | +5.1% | +6.3% | +11.1% | +8.4% | — |
| May 9, 2024 | AMC | -0.71 | -0.86 | -21.1% | 23.69 | +2.5% | +7.4% | +8.8% | +8.0% | +4.3% | +8.3% | — |
| Mar 8, 2024 | AMC | -0.36 | -0.49 | -36.1% | 24.71 | -0.9% | +6.4% | +3.8% | +3.6% | +4.3% | +6.5% | — |
| Nov 7, 2023 | AMC | -0.48 | -0.60 | -25.0% | 16.26 | -0.3% | -6.2% | -6.8% | -1.6% | -2.2% | -1.1% | — |
| Aug 8, 2023 | AMC | -0.52 | -0.59 | -13.5% | 15.65 | +4.5% | +3.2% | +4.2% | +4.7% | +1.1% | -1.0% | — |
| May 9, 2023 | AMC | -0.50 | -0.98 | -96.0% | 18.31 | +0.7% | +2.7% | +1.3% | +4.5% | +9.6% | +12.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.76 | $28.89 | +0.5% | -0.2% | +3.5% | +1.6% | +5.0% | +6.2% |
| Feb 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $25.32 | $25.79 | +1.9% | +6.8% | +5.6% | +5.7% | +0.8% | +3.5% |
| Dec 11 | Leerink Partners | Maintains | Outperform → Outperform | — | $34.36 | $27.90 | -18.8% | -22.8% | -26.6% | -25.8% | -24.8% | -26.5% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.36 | $27.90 | -18.8% | -22.8% | -26.6% | -25.8% | -24.8% | -26.5% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.92 | $24.98 | +0.2% | +0.9% | +2.3% | -0.6% | -2.8% | -2.1% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.97 | $20.94 | -0.1% | -3.1% | -5.0% | -8.0% | -5.7% | -5.5% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.89 | $20.89 | +0.0% | +0.0% | +0.8% | -0.0% | +0.2% | -0.7% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.61 | $26.13 | -1.8% | -6.5% | -3.3% | -1.0% | -1.9% | -4.0% |
| Jan 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.27 | $26.19 | -0.3% | -2.3% | -2.0% | -4.1% | -3.3% | +1.7% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.03 | $27.74 | -1.0% | -3.1% | -0.7% | -3.2% | -9.9% | -10.4% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.43 | $32.38 | -0.2% | -2.4% | -2.1% | -7.1% | -7.0% | -6.5% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.45 | $34.78 | +4.0% | -3.0% | -5.4% | -5.1% | -9.9% | -9.9% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.65 | $28.99 | +1.2% | +1.6% | +3.0% | +3.0% | +5.5% | +11.4% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.85 | $29.68 | -0.6% | -5.6% | -9.2% | -9.8% | -12.5% | -14.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.16 | $26.50 | +1.3% | +6.3% | +7.5% | +12.4% | +9.7% | +10.8% |
| Jul 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.65 | $24.82 | +0.7% | -0.4% | +4.2% | +6.2% | +9.5% | +9.4% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.24 | $24.80 | -1.7% | +2.2% | -4.6% | -3.0% | -3.6% | -5.0% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.34 | $25.28 | -0.2% | +1.9% | +0.4% | -2.2% | -1.3% | -3.2% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.64 | $25.55 | -0.4% | -1.1% | -0.9% | +3.4% | -1.2% | +0.7% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.71 | $24.49 | -0.9% | +6.4% | +3.8% | +3.6% | +4.3% | +6.5% |
| Feb 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.18 | $22.50 | +1.4% | +4.3% | +0.5% | +10.5% | +5.2% | +5.1% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.08 | $17.89 | -1.1% | +1.8% | +3.7% | +3.5% | +4.8% | +2.3% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.54 | $15.42 | -0.8% | +1.7% | +5.9% | +14.0% | +4.7% | +4.1% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.65 | $16.35 | +4.5% | +3.2% | +4.2% | +4.7% | +1.1% | -1.0% |
| Jun 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.57 | $18.70 | +0.7% | +4.2% | -0.3% | -3.7% | -2.3% | -1.1% |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.18 | $17.44 | +1.5% | -0.2% | -0.5% | +8.8% | +8.1% | +12.6% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.66 | $23.92 | +1.1% | +9.0% | +16.5% | +9.0% | +4.5% | +7.8% |
| Sep 9 | Aegis Capital | Maintains | Buy → Buy | — | $25.38 | $25.66 | +1.1% | +0.0% | +2.6% | -0.2% | -5.8% | -4.2% |
| Sep 7 | Wedbush | Downgrade | Outperform → Neutral | — | $28.88 | $27.00 | -6.5% | -12.5% | -12.1% | -12.1% | -9.8% | -12.3% |
| Sep 5 | Wedbush | Upgrade | Neutral → Outperform | — | $11.18 | $11.50 | +2.9% | +44.2% | +43.4% | +61.4% | +63.6% | +58.1% |
| Nov 14 | Wedbush | Downgrade | Outperform → Neutral | — | $6.58 | $6.70 | +1.8% | +2.6% | +11.4% | +10.0% | +5.9% | +1.1% |
| Jul 23 | Jefferies | Downgrade | Buy → Hold | — | $20.00 | $21.20 | +6.0% | +4.0% | -6.0% | -18.0% | -12.0% | -17.0% |
| Jun 29 | Susquehanna | Downgrade | Positive → Neutral | — | $78.40 | $77.00 | -1.8% | -6.6% | -1.0% | -4.3% | -4.8% | -1.5% |
| Mar 12 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $74.40 | $73.40 | -1.3% | +1.6% | -0.8% | +0.0% | +5.4% | +7.0% |
| Nov 10 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $76.20 | $75.60 | -0.8% | +2.4% | +6.0% | +7.1% | +4.2% | +2.9% |
| Apr 29 | McNicoll Lewis Vlak | Upgrade | Hold → Buy | — | $76.40 | $82.20 | +7.6% | +20.2% | +16.2% | +14.7% | +12.6% | +21.7% |
| Mar 11 | McNicoll Lewis Vlak | Downgrade | Buy → Hold | — | $128.60 | $122.00 | -5.1% | -8.7% | -5.8% | -4.4% | -6.4% | -7.5% |
| Mar 5 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $188.80 | $145.40 | -23.0% | -27.8% | -30.6% | -32.9% | -31.9% | -37.8% |
| Mar 4 | Credit Suisse | Downgrade | Outperform → Neutral | — | $178.20 | $182.20 | +2.2% | +5.9% | -23.5% | -26.5% | -29.0% | -27.8% |
| May 9 | Canaccord Genuity | Upgrade | Hold → Buy | — | $62.60 | $71.60 | +14.4% | +22.4% | +26.8% | +37.4% | +33.5% | +34.8% |
| Jan 7 | Wedbush | Maintains | Outperform → Outperform | — | $55.00 | $55.00 | +0.0% | +5.1% | +7.6% | +7.6% | +3.6% | +2.9% |
| May 9 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $62.00 | $61.20 | -1.3% | -11.9% | -20.3% | -15.5% | -16.5% | -18.7% |
| Mar 20 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $47.00 | $48.00 | +2.1% | -1.3% | -0.4% | -5.5% | -6.8% | +0.9% |
No insider trades available.
8-K · 2.02
!! High
Ligand Pharmaceuticals Incorporated -- 8-K 2.02: Earnings Results
Ligand Pharmaceuticals announced Q1 2026 earnings results, providing investors with updated financial performance and operational metrics for the three-month period ending March 31, 2026.
May 7
8-K
XOMA ROYALTY CORP - XOMA 8 5/8 PERP -- 8-K Filing
Legendarily XOMA Royalty shareholders will receive cash and contingent value rights tied to RemainCo LLC interests in the merger, providing potential future payments beyond immediate consideration.
Apr 27
8-K
Unknown — 8-K Filing
XOMA's significant portfolio expansion of 22 assets and two platform technologies positions the royalty aggregator for diversified revenue streams and reduced single-asset dependency, making it attractive for investors seeking biotech exposure with lower development risk.
Mar 18
8-K · 7.01
! Medium
XOMA Royalty Corporation -- 8-K 7.01: Regulation FD Disclosure
XOMA Royalty Corporation disclosed information under Regulation FD, requiring simultaneous public disclosure to all investors to ensure fair access to material company information.
Mar 2
8-K
XOMA Royalty Corporation -- 8-K Filing
XOMA Royalty Corporation initiated a tender offer with an Offer to Purchase and Letter of Transmittal filed on Schedule TO, allowing shareholders to tender shares under specified terms.
Feb 9
8-K
XOMA Royalty Corporation -- 8-K Filing
XOMA Royalty Corporation completed its post-offer reorganization with LAVA on November 20, 2025, concluding the subsequent offering period and effectuating the planned corporate restructuring.
Feb 2
Data updated apr 27, 2026 10:41am
· Source: massive.com